List view / Grid view
TALZENNA® is the first PARP inhibitor approved in combination with…
TALZENNA® is the first PARP inhibitor approved in combination with XTANDI for metastatic castration-resistant prostate cancer (mCRPC) in the EU.
As the next stage of their co-development of vepdegestrant, the…
As the next stage of their co-development of vepdegestrant, the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Pfizer and Arvinas its Innovation Passport to advance development of the oestrogen receptor (ER) degrader for ER+HER2- breast cancer.
To advance cancer breakthroughs, antibody-drug conjugates (ADCs) are the central…
To advance cancer breakthroughs, antibody-drug conjugates (ADCs) are the central technology in Pfizer’s intended acquisition of Seagen Inc.
A bispecific antibody for multiple myeloma gets Breakthrough Therapy Designation…
A bispecific antibody for multiple myeloma gets Breakthrough Therapy Designation based on 61 percent overall response trial data.
